The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnpario Regulatory News (ANP)

Share Price Information for Anpario (ANP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 255.00
Bid: 250.00
Ask: 260.00
Change: 0.00 (0.00%)
Spread: 10.00 (4.00%)
Open: 255.00
High: 255.00
Low: 255.00
Prev. Close: 255.00
ANP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Full Year Trading Statement

9 Jan 2023 07:00

RNS Number : 0159M
Anpario PLC
09 January 2023
 
 Anpario plc("Anpario" or the "Group")

 

Full Year Trading Statement

 

Anpario, the independent manufacturer of natural sustainable animal feed additives for health, nutrition and biosecurity, provides the following trading update for the year ended 31 December 2022.

 

Trading update

The Group experienced a weaker than expected final quarter, and in particular December's performance was adversely affected by several factors including our Chinese subsidiary where customer orders were impacted by the spread of Covid following the relaxation of restrictions. Other factors included orders which left the factory on time but were delayed at the port due to last minute shipping schedule changes and therefore missed the statutory cut-off period and certain other orders waiting for letters of credit and import permits which are now expected in early 2023.

 

During the year the Group experienced significant headwinds including raw material and logistics costs increases which reduced our margins, although margins did improve in the second half. Our customers have also been impacted by cost pressures, notably feed and energy, which is hurting their profitability and, in some cases, viability leading to reduced volumes of our products.

 

As previously announced in our interim report in September, the Group had legal and professional costs in relation to specific acquisition opportunities that did not proceed. For the full-year results, due to the exceptional and non-recurring nature of these costs, they will be excluded from our alternative profit measures such as adjusted EBITDA.

 

As a result of these factors, and subject to audit, we expect full year sales to be at least £33m and adjusted EBITDA1 to be not less than £5m.

 

We expect the global economy to continue to be challenging, however, we are encouraged by the improvement in our gross margins in recent months as a result of our actions to increase sales prices and are experiencing an easing of raw material price inflation, both of which are helping the Group to rebuild its margins. We continue to invest in our global sales teams and product development which will help deliver profitable growth of the Group.

Financial position

Our financial position remains strong with year-end cash balances of £13.6m (30 Jun 2022: £13.3m). Through the second half of the year we increased cash by £0.3m, after £2.2m of dividend payments and further capital investments. Global logistics have been challenging over the past 18 months and in order to ensure supply to our customers we built up contingency in our inventory. However, the situation has started to improve and as such we have been able to start to reduce our working capital requirements and this process will continue into the new year.

 

Final results date

The Group expects to announce its final results for the year ended 31 December 2022 on 22 March 2023.

 

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Group's obligations under Article 17 of MAR.

 

 

1 Adjusted EBITDA represents operating profit for the year adjusted for: acquisition costs; share based payments and associated costs; and depreciation, amortisation and impairment charges.

 

 

 

Enquiries

 

Anpario plc

 

Richard Edwards, CEO

+44(0)7776 417 129

Marc Wilson, Group Finance Director

+44(0)1909 537 380

 

 

Peel Hunt LLP (NOMAD)

+44(0)20 7418 8900

Adrian Trimmings

 

Andrew Clark

 

Lalit Bose

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPUAAGUPWPUR
Date   Source Headline
21st Mar 202411:37 amRNSDirector/PDMR Shareholding
21st Mar 20247:00 amRNSDirector/PDMR Shareholding
5th Feb 20247:00 amRNSAward of Options and Director/PDMR Shareholding
24th Jan 20247:00 amRNSFull year trading statement
17th Jan 20247:00 amRNSBlock listing Interim Review
5th Oct 20239:23 amRNSDirector Disclosure
13th Sep 20237:00 amRNSHalf-year Report
25th Aug 20235:10 pmRNSBlock listing Interim Review
1st Aug 20237:00 amRNSDirectorate Change
10th Jul 20232:14 pmRNSHolding(s) in Company
7th Jul 20232:34 pmRNSHolding(s) in Company
29th Jun 20233:57 pmRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
23rd Jun 20237:00 amRNSResult of Tender Offer
19th Jun 20232:48 pmRNSGM Statement
15th Jun 20237:00 amRNSShareholder Tour
7th Jun 20234:09 pmRNSReplacement - Tender Offer
6th Jun 20237:00 amRNSPosting of Annual Report and Notice of AGM
2nd Jun 20237:00 amRNSTender Offer
23rd May 20237:00 amRNSChange of Adviser
19th May 20234:40 pmRNSDirector Disclosures
19th May 20233:35 pmRNSTotal Voting Rights
5th May 20237:00 amRNSDirectorate Change
21st Apr 20237:00 amRNSAnpario receives King’s Award for Enterprise
11th Apr 20237:00 amRNSDirector/PDMR Shareholding
31st Mar 20231:13 pmRNSHolding(s) in Company
28th Mar 20237:00 amRNSDirector/PDMR Shareholding
22nd Mar 20237:00 amRNSFinal Results
3rd Feb 20237:00 amRNSDirector/PDMR Shareholding
24th Jan 202312:56 pmRNSBlock listing Interim Review
9th Jan 20237:00 amRNSFull Year Trading Statement
16th Dec 20227:00 amRNSAnpario receives ISO 14001 Certification
4th Nov 202212:52 pmRNSTotal Voting Rights
19th Oct 20227:00 amRNSDirector/PDMR Shareholding - Replacement
18th Oct 20227:00 amRNSDirector/PDMR Shareholding
6th Oct 20227:00 amRNSESG Initiatives
3rd Oct 20222:32 pmRNSDirector/PDMR Shareholding
14th Sep 20227:00 amRNSHalf-year Report
5th Sep 202212:38 pmRNSTotal Voting Rights
5th Aug 20222:00 pmRNSBob The Pigeon Back Home in Gateshead, Pet!
20th Jul 20221:02 pmRNSBlock listing Interim Review
7th Jul 20222:59 pmRNSHolding(s) in Company
22nd Jun 202211:24 amRNSAGM Statement
16th Jun 20226:00 pmRNSResult of AGM
16th Jun 20227:00 amRNSAGM Statement
27th May 202212:56 pmRNSHolding(s) in Company
24th May 20221:10 pmRNSHolding(s) in Company
11th May 20227:00 amRNSNotice of AGM
10th May 20223:55 pmRNSHolding(s) in Company
5th May 20223:18 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.